接种无蛋流感疫苗的老年人体液免疫应答相关因素
研究纳入91名≥56岁社区居住老年人,接种2018-2019年度无蛋流感疫苗,其中84人(92.3%)接种四价重组流感疫苗(RIV4,Flublok,Sanofi Pasteur),7人(7.7%)接种四价细胞培养流感疫苗(ccIIV4,Flucelvax,Seqirus)。接种前血清阳性率A(H1N1)为52.8%、A(H3N2)为94.5%、B/Colorado为61.5%、B/Phuket为48.4%;血清转化率范围为16.5%(A(H1N1)和B/Colorado)至37.4%(A(H3N2)),40名参与者对任何抗原均未血清转化。多变量模型中,接种前HAI抗体滴度较低(A(H1N1)、B/Colorado、B/Phuket)和较年轻年龄(A(H1N1))与较高GMFR独立相关。
要点
- 91名≥56岁老年人接种无蛋流感疫苗,接种前血清阳性率A(H3N2)最高(94.5%),B/Phuket最低(48.4%)。
- 血清转化率范围为16.5%(A(H1N1)和B/Colorado)至37.4%(A(H3N2)),40名参与者对任何抗原均未血清转化。
- 接种前HAI抗体滴度较低与较高GMFR独立相关(A(H1N1)、B/Colorado、B/Phuket),A(H1N1)中较年轻年龄与较高GMFR独立相关。
核心结论
- 总体接种前血清阳性率高,略超过一半的队列对至少1种疫苗抗原发生血清转化。
- 接种前抗体滴度较低的参与者抗体应答最高。
- 在接种前抗体滴度高的老年人中,需要改善免疫应答的方法。
研究设计与样本
- 前瞻性观察性研究,纳入社区居住的≥56岁老年人,评估2018-2019年度无蛋流感疫苗的免疫原性。
- 共91名参与者,其中84名(92.3%)接种四价重组流感疫苗(RIV4,Flublok,Sanofi Pasteur),7名(7.7%)接种四价细胞培养流感疫苗(ccIIV4,Flucelvax,Seqirus)。
- 接种前(第0天)和接种后4周(第28天)测量血凝抑制(HAI)抗体滴度,计算几何平均滴度、血清阳性(HAI滴度≥1:40)、血清转化(HAI滴度四倍升高且接种后滴度≥1:40)和几何平均倍数升高(GMFR)。
- 采用线性回归模型评估各疫苗抗原GMFR预测因素的关联。
主要发现
- 接种前血清阳性率:A(H1N1)为52.8%,A(H3N2)为94.5%,B/Colorado为61.5%,B/Phuket为48.4%。
- 血清转化率按抗原范围为16.5%(A(H1N1)和B/Colorado)至37.4%(A(H3N2))。
- 40名参与者对任何抗原均未发生血清转化。
- 多变量模型中,与较高GMFR独立相关的因素包括:A(H1N1)、B/Colorado和B/Phuket的接种前HAI抗体滴度较低,以及A(H1N1)的较年轻年龄。
关键数值与推荐
- 血清阳性定义为HAI滴度≥1:40。
- 血清转化定义为HAI滴度四倍升高且接种后滴度≥1:40。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune responses to influenza vaccination tend to be lower among older, frequently vaccinated adults. Use of egg-free influenza vaccines is increasing, but limited data exist on factors associated with their immunogenicity in older adults. METHODS: Community-dwelling older adults ≥ 56 years of age were enrolled in a prospective, observational study of immunogenicity of 2018-2019 influenza vaccine. Hemagglutination inhibition (HAI) antibody titers were measured pre-vaccination (Day 0) and four weeks after vaccination (Day 28) to calculate geometric mean titers, seropositivity (HAI titers ≥ 1:40), seroconversion (fourfold rise in HAI titer with post-vaccination titer ≥ 1:40) and geometric mean fold rise (GMFR). Linear regression models assessed the association of predictors of GMFR for each vaccine antigen. RESULTS: Among 91 participants who received egg-free influenza vaccines, 84 (92.3 %) received quadrivalent recombinant influenza vaccine (RIV4, Flublok, Sanofi Pasteur), and 7 (7.7 %) received quadrivalent cell culture-based influenza vaccine (ccIIV4, Flucelvax, Seqirus). Pre-vaccination seropositivity was 52.8 % for A(H1N1), 94.5 % for A(H3N2), 61.5 % for B/Colorado and 48.4 % for B/Phuket. Seroconversion by antigen ranged from 16.5 % for A(H1N1) and B/Colorado to 37.4 % for A(H3N2); 40 participants failed to seroconvert to any antigen. Factors independently associated with higher GMFR in multivariable models included lower pre-vaccination HAI antibody titer for A(H1N1), B/Colorado and B/Phuket, and younger age for A(H1N1). CONCLUSION: Overall pre-vaccination seropositivity was high and just over half of the cohort seroconverted to ≥ 1 vaccine antigen. Antibody responses were highest among participants with lower pre-vaccination titers. Among older adults with high pre-existing antibody titers, approaches to improve immune responses are needed.
引用
- Williams KV, Moehling Geffel K, Alcorn JF, et al. Factors associated with humoral immune response in older adults who received egg-free influenza vaccine. Vaccine. 2022. PMID: 36543682. doi:10.1016/j.vaccine.2022.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。